Relationship between pre-existing viral reservoirs and the re-emergence of plasma viremia after discontinuation of highly active anti-retroviral therapy
- PMID: 10888923
- DOI: 10.1038/77481
Relationship between pre-existing viral reservoirs and the re-emergence of plasma viremia after discontinuation of highly active anti-retroviral therapy
Abstract
We examined the pathogenic significance of the latent viral reservoir in the resting CD4+ T cell compartment of HIV-1-infected individuals as well as its involvement in the rebound of plasma viremia after discontinuation of highly active anti-retroviral therapy (HAART). Using heteroduplex mobility and tracking assays, we show that the detectable pool of latently infected, resting CD4+ T cells does not account entirely for the early rebounding plasma HIV in infected individuals in whom HAART has been discontinued. In the majority of patients examined, the rebounding plasma virus was genetically distinct from both the cell-associated HIV RNA and the replication-competent virus within the detectable pool of latently infected, resting CD4 + T cells. These results indicate the existence of other persistent HIV reservoirs that could prompt rapid emergence of plasma viremia after cessation of HAART and underscore the necessity to develop therapies directed toward such populations of infected cells.
Comment in
-
HIV-1 rebound after anti-retroviral therapy.Nat Med. 2000 Jul;6(7):736-7. doi: 10.1038/77447. Nat Med. 2000. PMID: 10888912 No abstract available.
Similar articles
-
Gene expression and viral prodution in latently infected, resting CD4+ T cells in viremic versus aviremic HIV-infected individuals.Proc Natl Acad Sci U S A. 2003 Feb 18;100(4):1908-13. doi: 10.1073/pnas.0437640100. Epub 2003 Jan 27. Proc Natl Acad Sci U S A. 2003. PMID: 12552096 Free PMC article.
-
Effect of interleukin-2 on the pool of latently infected, resting CD4+ T cells in HIV-1-infected patients receiving highly active anti-retroviral therapy.Nat Med. 1999 Jun;5(6):651-5. doi: 10.1038/9498. Nat Med. 1999. PMID: 10371503 Clinical Trial.
-
In vitro induction of HIV-1 replication in resting CD4(+) T cells derived from individuals with undetectable plasma viremia upon stimulation with human T-cell leukemia virus type I.Virology. 2000 Dec 20;278(2):514-9. doi: 10.1006/viro.2000.0684. Virology. 2000. PMID: 11118373
-
Reservoirs of HIV-1 in vivo: implications for antiretroviral therapy.AIDS Rev. 2003 Jan-Mar;5(1):3-18. AIDS Rev. 2003. PMID: 12875103 Review.
-
Molecular biological assessment methods and understanding the course of the HIV infection.APMIS Suppl. 2003;(114):1-37. APMIS Suppl. 2003. PMID: 14626050 Review.
Cited by
-
Colony-Stimulating Factor 1 Receptor Antagonists Sensitize Human Immunodeficiency Virus Type 1-Infected Macrophages to TRAIL-Mediated Killing.J Virol. 2016 Jun 24;90(14):6255-6262. doi: 10.1128/JVI.00231-16. Print 2016 Jul 15. J Virol. 2016. PMID: 27122585 Free PMC article.
-
Molecular Understanding of HIV-1 Latency.Adv Virol. 2012;2012:574967. doi: 10.1155/2012/574967. Epub 2012 Apr 4. Adv Virol. 2012. PMID: 22548060 Free PMC article.
-
Viral evolution during structured treatment interruptions in chronically human immunodeficiency virus-infected individuals.J Virol. 2002 Dec;76(23):12344-8. doi: 10.1128/jvi.76.23.12344-12348.2002. J Virol. 2002. PMID: 12414975 Free PMC article.
-
Genetic characterization of rebounding human immunodeficiency virus type 1 in plasma during multiple interruptions of highly active antiretroviral therapy.J Virol. 2003 Mar;77(5):3229-37. doi: 10.1128/jvi.77.5.3229-3237.2003. J Virol. 2003. PMID: 12584346 Free PMC article. Clinical Trial.
-
Gastrointestinal tract and the mucosal macrophage reservoir in HIV infection.Clin Vaccine Immunol. 2014 Nov;21(11):1469-73. doi: 10.1128/CVI.00518-14. Epub 2014 Sep 3. Clin Vaccine Immunol. 2014. PMID: 25185575 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials